Understanding the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma

Overview

Journal Clin Transl Immunology

Specialty Allergy & Immunology

Date 2022 Jun 10

PMID 35686027

Authors

Habib Sadeghi Rad

Yavar Shiravand

Payar Radfar

Rahul Ladwa

Chris Perry

Xiaoyuan Han

Majid Ebrahimi Warkiani

Mark N Adams

Brett Gm Hughes

Ken OByrne

Arutha Kulasinghe

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors. While significant progress has been made using multimodal treatment, the 5-year survival remains at 50%. Developing effective therapies, such as immunotherapy, will likely lead to better treatment of primary and metastatic disease. However, not all HNSCC tumors respond to immune checkpoint blockade therapy. Understanding the complex cellular composition and interactions of the tumor microenvironment is likely to lead to new knowledge for effective therapies and treatment resistance. In this review, we discuss HNSCC characteristics, predictive biomarkers, factors influencing immunotherapy response, with a focus on the tumor microenvironment.

Citing Articles

Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.

Li H, Gong Y, Yan P, Xu Y, Qin G, Wen W Front Immunol. 2024; 15:1453753.

PMID: 39676875 PMC: 11638222. DOI: 10.3389/fimmu.2024.1453753.

Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer.

Vesela K, Kejik Z, Masarik M, Babula P, Dytrych P, Martasek P ACS Pharmacol Transl Sci. 2024; 7(11):3394-3418.

PMID: 39539276 PMC: 11555516. DOI: 10.1021/acsptsci.4c00518.

Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response.

Sadeghirad H, Monkman J, Tan C, Liu N, Yunis J, Donovan M J Transl Med. 2024; 22(1):677.

PMID: 39049036 PMC: 11267849. DOI: 10.1186/s12967-024-05409-y.

Type I conventional dendritic cells and CD8 T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients.

Kirchner J, Plesca I, Rothe R, Resag A, Lock S, Benesova I Front Immunol. 2024; 15:1414298.

PMID: 38938577 PMC: 11208331. DOI: 10.3389/fimmu.2024.1414298.

Role of Microenvironmental Components in Head and Neck Squamous Cell Carcinoma.

Jumaniyazova E, Lokhonina A, Dzhalilova D, Kosyreva A, Fatkhudinov T J Pers Med. 2023; 13(11).

PMID: 38003931 PMC: 10672525. DOI: 10.3390/jpm13111616.

References

Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T . Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma. Front Immunol. 2017; 8:387. PMC: 5385630. DOI: 10.3389/fimmu.2017.00387. View

Tay R, Richardson E, Toh H . Revisiting the role of CD4 T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2020; 28(1-2):5-17. PMC: 7886651. DOI: 10.1038/s41417-020-0183-x. View

Chai A, Lim K, Cheong S . Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2019; 61:71-83. DOI: 10.1016/j.semcancer.2019.09.011. View

de Ruiter E, Ooft M, Devriese L, Willems S . The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Oncoimmunology. 2017; 6(11):e1356148. PMC: 5674970. DOI: 10.1080/2162402X.2017.1356148. View

Balermpas P, Rodel F, Krause M, Linge A, Lohaus F, Baumann M . The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer. 2017; 141(3):594-603. DOI: 10.1002/ijc.30770. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Ortiz-Otero N, Clinch A, Hope J, Wang W, Reinhart-King C, King M . Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression. Oncotarget. 2020; 11(12):1037-1050. PMC: 7105166. DOI: 10.18632/oncotarget.27510. View

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

Chen W, Ten Dijke P . Immunoregulation by members of the TGFβ superfamily. Nat Rev Immunol. 2016; 16(12):723-740. DOI: 10.1038/nri.2016.112. View

10.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

11.

Bristow R, Hill R . Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008; 8(3):180-92. DOI: 10.1038/nrc2344. View

12.

Hashimoto M, Kamphorst A, Im S, Kissick H, Pillai R, Ramalingam S . CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annu Rev Med. 2018; 69:301-318. DOI: 10.1146/annurev-med-012017-043208. View

13.

Hanna G, Lizotte P, Cavanaugh M, Kuo F, Shivdasani P, Frieden A . Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018; 3(4). PMC: 5916245. DOI: 10.1172/jci.insight.98811. View

14.

Abel A, Yang C, Thakar M, Malarkannan S . Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9:1869. PMC: 6099181. DOI: 10.3389/fimmu.2018.01869. View

15.

. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576-82. PMC: 4311405. DOI: 10.1038/nature14129. View

16.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

17.

Van Allen E, Miao D, Schilling B, Shukla S, Blank C, Zimmer L . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211. PMC: 5054517. DOI: 10.1126/science.aad0095. View

18.

Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R . Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018; 175(4):998-1013.e20. PMC: 6641984. DOI: 10.1016/j.cell.2018.10.038. View

19.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

20.

Hirsch F, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K . PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2016; 12(2):208-222. DOI: 10.1016/j.jtho.2016.11.2228. View